Smith & Nephew plc (LON:SN) has been given a “Moderate Buy” consensus rating by seven different ratings firms, according to MarketBeat Ratings. Among these firms, one analyst has a sell recommendation, one has a hold recommendation, and five have issued a buy recommendation for the company. Over the past year, the average price objective set by these brokerages is GBX 1,375.50 ($17.10).

Various research analysts have recently shared their opinions on Smith & Nephew. Berenberg Bank, for example, raised their price target from GBX 1,400 ($17.40) to GBX 1,500 ($18.65) and gave the stock a “buy” rating in a research report. Barclays also raised their price objective from GBX 1,100 ($13.67) to GBX 1,200 ($14.92) and issued an “underweight” rating for the company. In addition, Liberum Capital upgraded Smith & Nephew to a “buy” rating and increased their price objective from GBX 1,120 ($13.92) to GBX 1,410 ($17.53).

On Friday, Smith & Nephew opened at GBX 1,197 ($14.88). The stock’s 50-day simple moving average is GBX 1,230.87, while the 200-day simple moving average stands at GBX 1,172.07. Its one-year low is GBX 959.20 ($11.92), and the one-year high is GBX 1,316.75 ($16.37). With a market capitalization of £10.45 billion and a P/E ratio of 5,700.00, Smith & Nephew operates with a price-to-earnings-growth ratio of 0.97 and a beta of 0.37. The company has a debt-to-equity ratio of 54.61, a current ratio of 2.25, and a quick ratio of 0.84.

Smith & Nephew plc, along with its subsidiaries, is involved in the development, manufacturing, marketing, and selling of medical devices worldwide. Their product offerings include knee and hip implant products for joint replacement procedures, as well as trauma and extremities products used for the stabilization of severe fractures and deformity correction procedures.